Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zirabev (PF-06439535) vs Bevacizumab-EU in Chinese Patients with Advanced Non-Squamous NSCLC
NCT04325698Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-bvzr in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Objective Response Rate at Week 25. Started Jun 2020; status: terminated.
02
Drugs
bevacizumab-bvzr
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04325698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325698.